AMBOSS is a Berlin-based medical education technology company founded in 2012 that provides a comprehensive digital platform for medical students, physicians, nurses, and educators worldwide.[1][2][3][5] It offers a knowledge library, question bank (Qbank) with over 11,000 practice questions covering USMLE, COMLEX, NBME Shelf, and specialty board exams, integrated articles, AI-driven insights, and clinical decision-support tools to enhance learning, exam preparation, and daily practice.[3][4] Serving more than 500,000 users across 170+ countries and trusted by 350+ U.S. medical schools, AMBOSS solves the challenge of fragmented medical education by integrating research-based content, spaced repetition via Anki add-ons, and analytics for personalized study plans, with paid plans starting at $20/month.[1][3][4] The company has demonstrated strong growth through a €240 million ($260M) funding round in 2024 for global expansion, acquisitions like Novaheal (nursing education) and NEJM Knowledge+, and partnerships with institutions like Saint James School of Medicine.[2]
AMBOSS was launched in 2012 in Berlin, Germany, by a group of young doctors, including co-founder Sievert Weiss, who is passionate about improving global health through education, alongside figures like Lorenz Geenen and George Hadjichristofis in business development roles.[1] The idea emerged as a one-stop medical education platform to promote best-in-class outcomes, evolving from a student-focused tool into a global knowledge engine built on cutting-edge medical research and technology.[1][5] Early traction built steadily, with a €30 million Series B in 2019 led by Partech and others, followed by massive 2024 funding from investors like Lightrock, M&G Investments, KIRKBI, Partech, and Wellington Partners, signaling readiness for IPO-scale ambitions.[1][2] Pivotal moments include 2024 acquisitions of Novaheal and NEJM Knowledge+, expanding into nursing and clinician tools, and integrations with curricula at schools like Saint James School of Medicine.[2]
AMBOSS rides the EdTech wave in healthcare, capitalizing on the post-pandemic shift to digital learning and AI-enhanced medical training amid clinician shortages and rising demand for lifelong education.[2][4] Timing aligns with global medical licensing pressures (e.g., USMLE backlogs) and nursing gaps, where its platform reduces study fragmentation—students juggle exams, rounds, and notes—by distilling vast research into actionable tools.[4] Market forces like evergreen investor backing for long-term growth (to IPO) and selective M&A favor AMBOSS, influencing the ecosystem through curriculum integrations, AMA partnerships, and expansions into non-physician roles, setting standards for AI-driven, accessible med-ed that boosts outcomes for 500,000+ users.[1][2][3]
AMBOSS is poised for accelerated global dominance in med-ed, leveraging its 2024 mega-round to penetrate new markets, deepen nurse/educator offerings, and pursue acquisitions or IPO amid AI-medicine trends.[2] Expect growth in multilingual support (e.g., German, Polish, Portuguese), advanced AI for predictive analytics, and ecosystem influence via more school partnerships, shaping how 2M+ professionals build knowledge amid evolving exams and telehealth demands.[2][4][5] As the go-to hub from classroom to clinic, AMBOSS exemplifies how doctor-led tech drives "best-in-class outcomes" worldwide.[1]
AMBOSS has raised $43.0M in total across 3 funding rounds.
AMBOSS's investors include Castle Island Ventures, StillMark, Atomico, Baidu Ventures, Cherry Ventures, Plug & Play Ventures.
AMBOSS has raised $43.0M across 3 funding rounds. Most recently, it raised $4.0M Seed in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $4.0M Seed | Castle Island Ventures, StillMark | |
| Jul 1, 2019 | $34.0M Series B | Atomico, Baidu Ventures, Cherry Ventures, Plug & Play Ventures | |
| Jan 1, 2017 | $5.0M Series A | Atomico, Baidu Ventures, Cherry Ventures, Plug & Play Ventures |
